Widely acknowledged as one of the most challenging aspects of dealing with an ageing population, the increasing prevalence of cognitive decline in the elderly presents the clinician with a variety of complex therapeutic problems. Alzheimer's disease and other dementias vary in their onset and progression, as do patients in their responsiveness to treatment. Social management is as important as the choice of therapeutic agent, and implementing effective and sympathetic treatment requires care and sensitivity as well as a sound knowledge of currently available options. In this important new work, leading experts review the therapeutic agents currently available and assess their effectiveness. Also included is an update on recent and on-going clinical trials, the prospects for new therapeutic targets and the development of new biomarkers that will aid recognition of disease and thus earlier intervention.
Indice testuale
Preface; Foreword; SECTION I: Current pharmacological approaches in dementia; 1. Cholinesterase inhibitors: synthesis of meta-analysis / randomised controlled trials, CW Ritchie; 2. Cholinesterase inhibitors: long-term studies, R Bullock; 3. Cholinesterase inhibitors: head-to-head studies, R Jones; 4. Ginkgo biloba, RW McCarney, J Warner; 5. Memantine, DW Wilkinson; 6. Anti-oxidants (vitamin E, n-acetyl-cysteine), M Sano; 7. Pharmacoeconomic studies, C Green; SECTION II: Biological developments and future therapies; 8. Disease modifying therapeutic strategies for Alzheimer's disease: targeting the APP/A-beta pathway, CL Masters; 9. Anti-inflammatory drugs, M Woodward; 10. Nicotine and A-beta, A Nordberg; 11. Butyl-cholinesterase, MR Farlow; 12. Sex hormones in the treatment of Alzheimer's disease, D Ames, K Draper; 13. Allosteric potentiating ligands, A Maelicke; 14. The utility of biomarkers in the diagnosis and monitoring of Alzheimer's disease, CW Ritchie; SECTION III: Management of non-cognitive issues in dementia; 15. Non-pharmacological intervention for BPSD, J Cohen-Mansfield; 16. Pharmacological intervention for BPSD, A Shah; 17. Management of affective disorders in dementia, A Thomas; 18. Management of vascular and other risks, R Stewart; 19. Social management of dementia for patient and carer, H Brodaty; SECTION IV: Treatment of non-Alzheimer's disease cognitive impairment; 20. Vascular dementia, T Erkinjuntti; 21. Frontotemporal dementia, M Ikeda; 22. Diffuse Lewy body disease and Parkinson's disease with dementia, R Barber; 23. Mild cognitive impairment (MCI), YE Geda; 24. Delirium, E Sampson; List of abbreviations; Index.
